News

Brief news reports on Tuberculosis

Local use of TB data in Zimbabwe led to improved data quality and better TB care

The results of a retrospective cohort study conducted by The Union in collaboration with the Zimbabwe National TB Control Programme (NTP) showed that empowering staff at local-level TB clinics to collect, tabulate, analyse and use their TB data, led to improvements in diagnoses and treatment.

Read More →

TB Europe Coalition: Capacity building workshop

The TB Europe Coalition launched a call for applications for a three-day capacity building workshop on TB advocacy and service delivery that will take place in London, UK on 16-18 September 2019.

Read More →

50th Union World Conference on Lung Health: Scholarship applications are now open

The Union offers a limited number of scholarships for individuals affected by lung disease, invited symposia speakers, authors of accepted abstracts and community volunteers.

Read More →

Management of TB in HIV patients: British HIV Association guideline

The British HIV Association has released an updated guideline for the management of TB in patients with HIV.

Read More →

Activists demand Johnson & Johnson drop the price of bedaquiline

Activists storm the corporate stall of Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) at the 9th South African AIDS Conference.

Read More →

New rapid test significantly more effective for TB diagnosis in people with HIV

Compared to the only other approved device for TB detection in people living with HIV, the new FujiLAM point-of-care test offers superior diagnostic sensitivity.

Read More →

Evotec receives $23.8 million grant to join the global fight against TB

  • The Bill & Melinda Gates Foundation Supports Evotec With A $ 23.8 M Grant To Generate Critical Data For Selecting Best Drug Combinations For Phase II Clinical Trials
  • Tuberculosis Is The Leading Cause Of Death Due To An Infectious Disease Worldwide
  • Five-Year Partnership Is Focused On Evaluating New Treatment Regimens That Can Substantially Reduce Treatment Time And Overcome Resistance To Current Therapies

HAMBURG, GERMANY, June 10, 2019 /Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis ("TB"), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide. The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant.

Read More →

Stanford researchers synthesize healing compounds in scorpion venom

Stanford chemists have identified and synthesized two new healing compounds in scorpion venom that are effective at killing staph and tuberculosis bacteria.

Read More →

Xpert Ultra test for diagnosing TB now included in Cochrane Review

Tuberculosis (TB) causes more deaths globally than any other infectious disease and is a top 10 cause of death worldwide. Globally in 2017, of the estimated 10 million people with TB, 3.6 million were not reported to national TB programmes, many of whom were not being diagnosed with their disease. When it is detected early and effectively treated, TB is largely curable, but in 2017, around 1.6 million people died of tuberculosis, including 300,000 people living with HIV.

Read More →

Aidspan publishes new issue of ‘Global Fund Observer’

Aidspan: Global Fund Observer

Read More →

Page 1 of 658 · Total posts: 10

1 2 Last→